NCT00418184View on ClinicalTrials.gov

The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2009

Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
DIETARY_SUPPLEMENT

Phosphatidylserine-Omega3

Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.

OTHER

Colored cellulose tainted with fishy odor

as arm 1

Trial Locations (1)

49100

ADHD Unit, Petach-Tiqva

Sponsors

Lead Sponsor

Enzymotec
All Listed Sponsors
lead

Enzymotec

INDUSTRY

NCT00418184 - The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder | Biotech Hunter | Biotech Hunter